- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03461094
Fluid Responsiveness Evaluation in Patients With Acute Circulatory Failure and Arrhythmia With Atrial Fibrillation: Indice Delta ITV / Delta RR
Fluid therapy is often used as first line treatment of acute circulatory failure, aiming an increase in cardiac output (by improving preload) and in tissue perfusion. Depending on left ventricular systolic function, fluid challenge could lead to an increase in cardiac ouput and tissue perfusion, or only detrimental consequences (by fluid overload and aggravation of lung and tissues oedema, increase of morbi-mortality). Patients are defined as responders to fluid therapy if one can observe an increase of cardiac output up to 15% after fluid therapy (500ml of crystalloids): gold standard test used in most of the studies on the subject. Literature reports on heterogenous populations a reproductible and constant response rate to this fluid challenge of 50%. It seems reasonable to dispose of indices allowing to predict fluid responsiveness without resulting in fluid intake. Statics markers have been abandonned for several years and dynamics methods have been developped.
In front of arrythmia, validated methods are scarce. Passive leg rising method appears to be the only one and it's validity seems to be less well documented than in sinusal patients. The purpose of this study is to determine a new method to assess fluid responsiveness in arrythmic patients.
In atrial fibrillation, RR interval varies widely between cardiac cylces. Systolic interval remain constant. Variations will occure at expense of diastolic interval, or ventricular filling interval. One can reliably assume that when RR is longer, preload is rising. If the patient is on the ascendant part of the Franck-Starling curve, a longer RR should cause au greater VTI (Vitess Time Integral, surrogate of cardiac output).
The evaluation by transthoracic echocardiography of the indice delta ITV / delta RR should determine the degree of fluid responsiveness in arrhythmic patients.
After decision of fluid expansion, patients will have haemodynamic and echocardiographic data measured, delta ITV / delta RR indice assessed, then passive leg rising and fluid expansion with 500 ml of cristalloids administered, with evaluation of VTI (as surrogate of cardiac output) at each time. Fluid responders will be compared to non-responders to evaluate the diagnostic performances of the indice delta ITV / delta RR.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Poitiers, France, 86021
- CHU de Poitiers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospitalized patients in the units of Surgical ICU and Cardiothoracic ICU of the Universatory Hospital of Poitiers
- With atrial Fibrillation
- With spontaneous ventilation
- With acute circulatory failure and medical decision to fluid therapy (Systolic Arterial Blood Pressure < 90 mmHg and/or vasopressors agents)
- With no left or right ventricular dysfunction
Exclusion Criteria:
- Patients < 18 yrs
- Contraindictions to passive leg rising
- Clinical evidence of hemorrhagic shock
- Cardiogenic shock
- Necessity of fluid expansion in emergency
- No echographic windows
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the diagnostic performance of the index deltaI ITV / delta RR
Time Frame: Fluid therapy taking 20 minutes, with responsiveness evaluation within the 5 minutes following fluid therapy
|
Increase of 15% or more of stroke volume after fluid therapy
|
Fluid therapy taking 20 minutes, with responsiveness evaluation within the 5 minutes following fluid therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Diagnostic performances of passive leg rising for prediction of fluid responsiveness
Time Frame: Fluid therapy taking 20 minutes, with responsiveness evaluation within the 5 minutes following fluid therapy
|
Fluid therapy taking 20 minutes, with responsiveness evaluation within the 5 minutes following fluid therapy
|
|
Diagnostic performances of respiratory variations of inferior vena cava for prediction of fluid responsiveness
Time Frame: Fluid therapy taking 20 minutes, with responsiveness evaluation within the 5 minutes following fluid therapy
|
Fluid therapy taking 20 minutes, with responsiveness evaluation within the 5 minutes following fluid therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Kerforne, Poitiers University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLUIDRESP ARYTHM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.